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A B S T R A C T
Objective: Preeclampsia, a multi-system hypertensive disorder, is associated with perturbations in the maternal
cardiovascular system during early pregnancy. The corpus luteal hormone relaxin, a potent vasodilator, may
contribute to physiological circulatory changes especially in early gestation when circulating levels are highest.
This study investigated whether first trimester circulating relaxin may be a suitable biomarker for the early
prediction of preeclampsia.
Methods: Relaxin was initially measured in first-trimester samples of women who developed late-onset pre-
eclamptic (LO-PE; delivery ≥ 34 weeks; n = 33) and uncomplicated pregnancies (n = 25) in Pittsburgh, USA.
Subsequently, to expand the group numbers, relaxin was measured in women who developed LO-PE (n = 95),
early-onset preeclamptic (EO-PE; delivery < 34 weeks; n = 57), and uncomplicated pregnancies (n = 469) in
Utrecht, the Netherlands.
Results: In the Pittsburgh subjects, low relaxin levels (lowest centile: < p10) showed an adjusted odds ratio (OR)
of 5.29 (95%CI 1.10–25.5) for LO-PE. In the Utrecht population, low relaxin levels (< p10) demonstrated ad-
justed ORs of 1.45 (95%CI 0.54–3.90) and 2.03 (95%CI 1.06–3.88) for EO-PE and LO-PE respectively, the latter
increasing to an adjusted OR of 3.18 (95%CI 1.41–7.20) when newborn weight was < 10%. Serum relaxin
concentrations slightly improved the detection rate of a previously derived prediction model for LO-PE from
42.5% to 45.1% at a fixed 10% false-positive rate.
Conclusion: Relaxin shows little improvement in the performance of first trimester prediction models, which
does not support its clinical implementation as a biomarker. Although this study was only correlational, the
results point to a possible pathophysiologic role for low relaxin levels in pregnancies that later develop LO-PE.
1. Introduction
Preeclampsia, a gestation-specific hypertensive syndrome affecting
3–5% of all pregnant women, is a leading cause of maternal and peri-
natal morbidity and mortality [1]. The exact etiology of preeclampsia
remains to be elucidated, although it is widely believed that pre-
eclampsia is a consequence of an inadequate maternal vascular
response to placentation during early pregnancy [2–5]. Due to impaired
placental function, women with preeclampsia often give birth to a small
for gestational age (SGA) infant [6,7]. In most cases (> 75%) pre-
eclampsia symptoms have a late-onset, developing after 34 weeks of
gestation (LO-PE) [8]. Early-onset preeclampsia (EO-PE) is associated
with more severe placental pathology [9,10], and a higher rate of fetal
growth restriction [11,12]. Both LO- and EO-PE confer an increased risk
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of cardiovascular disease later in life for the mother [13,14], and her
offspring [15]. Therefore, the early identification of pregnancies at high
risk for preeclampsia is still one of the major challenges of modern
obstetrics [16,17].
Relaxin is a peptide hormone secreted by the corpus luteum into the
maternal circulation during the late secretory phase of the menstrual
cycle and in pregnancy [18,19]. Relaxin is emerging as an important
regulator of the maternal vascular adaptations to pregnancy [20,21].
Moreover, relaxin may hold promise as a novel therapeutic intervention
for hypertensive pathologies, such as reduction of vascular wall stiff-
ness as demonstrated in preclinical models [22–24]. A low first trime-
ster serum relaxin concentration is associated with increased blood
pressure in the third trimester of pregnancy [25]. Moreover, pregnan-
cies achieved by oocyte donation that lack a corpus luteum, have no
detectable circulating relaxin and are at increased risk for hypertensive
disorders of pregnancy including preeclampsia [26,27]. Locally at the
maternal-fetal interface relaxin may be important in the vascular pre-
paration of the endometrium for placentation. In a non-human primate
model of early pregnancy, relaxin was shown to stimulate vascular-
ization as demonstrated by a significantly higher number of arterioles
in the endometrium [28–30]. In vitro studies corroborate these findings
as relaxin was shown to be a potent inducer of human endometrial
maturation (decidualization) and increases expression of angiogenic
factors such as vascular endothelial growth factor in endometrial cells
[31–33]. Therefore, women with low concentrations of circulating re-
laxin could experience defects in the establishment of a functional
maternal-fetal interface or fail to adequately vasodilate in early preg-
nancy, predisposing them to develop preeclampsia. The aim of this
work was to establish whether relaxin may be a suitable first trimester
biomarker in the early prediction of preeclampsia. We also evaluated
pregnancy-associated plasma protein A (PAPP-A), free beta human
chorionic gonadotrophin (fb-hCG), A Disintegrin And Metalloprotease
12 (ADAM-12) and placental growth factor (PlGF), previously estab-
lished as biomarkers of preeclampsia, in the context of relaxin.
2. Materials and methods
2.1. Study populations and ethics statement
We first performed a prospective pilot study at Magee-Womens
Research Institute at the Department of Obstetrics, Gynecology and
Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, USA
(‘Pittsburgh group’). To corroborate the findings of this initial study we
used a large Dutch nested case-control group collected at the Center for
Infectious Disease Research, Diagnostics and Screening at the National
Institute for Public Health and the Environment, Bilthoven, The
Netherlands (‘Dutch group’). The University of Pittsburgh Institutional
Review Board (protocol 0404159) and the Medical Ethical Committee
of the University Medical Center Utrecht (protocol 11-002) approved
the research protocols for the Pittsburgh and Dutch studies respectively.
The Pittsburgh population was a nested case-control study with
samples derived from a longitudinal, prospective group of pregnant
women studied for the development of preeclampsia and adverse
pregnancy outcomes at Magee-Womens Hospital, Pittsburg, PA. For a
detailed description we refer to a previous publication of this group
[34]. The overall prevalence of preeclampsia in this group was 3.8%
and gestational hypertension 6.4%. The study consisted of 33 women
who developed LO-PE and 25 normotensive women with un-
complicated pregnancies matched for gestational age of sample col-
lection, parity, and race. Blood samples were collected at 5+0-12+1
gestational weeks and plasma was aliquoted and stored at −80 °C until
analysis. Maternal characteristics were obtained through interviews
and detailed medical record abstraction and review. Pregnancy out-
comes, including the diagnosis of preeclampsia, were determined ret-
rospectively based on medical chart review by a jury of research and
clinical investigators.
The Dutch population was a nested case-control study with serum
samples derived from a large national group of women participating in
the routine first trimester Down syndrome screening and has been used
for previous studies by our group. For a detailed description we refer to
two previous publications of this group [35,36]. In short, blood samples
were collected at 9+1–13+6 gestational weeks and serum was aliquoted
and stored at −80 °C until analysis. Pregnancy outcomes including
chromosomal disorders, date of birth, birth weight and hypertensive
disorders (pregnancy induced hypertension, preeclampsia, HELLP syn-
drome) were collected through self-reporting of participating women
and confirmed by consultation with the participating clinics, where also
maternal characteristics were obtained (i.e. medical history, parity,
weight, height, first trimester blood pressure, smoking status) that were
recorded by a midwife or gynecologist. The LO-PE group was selected
to have a small for gestational age (SGA) infant in half of the cases.
2.2. Outcome measures
Preeclampsia was defined as the new onset of hypertension (≥140/
90 mmHg) after 20 weeks of gestation measured on at least two sepa-
rate occasions at least four hours apart, combined with the presence of
proteinuria (a 24-hour collection of urine with ≥ 300 mg/24 h or at
least 2 + by dipstick on a spot urinalysis), according to the criteria of
the International Society for the Study of Hypertension in Pregnancy
[37]. (The definition of preeclampsia has since changed, insofar as
proteinuria is no longer a requirement for the diagnosis [38]. But when
the current study was conducted, the older definition was in place.) EO-
PE was defined as preeclampsia necessitating delivery < 34 weeks
gestational age, and LO-PE as preeclampsia in pregnancies deli-
vering ≥ 34 weeks. To calculate birth weight z-score, the 2008 growth
charts from The Netherlands Perinatal Registry (PRN, now Perined)
were used [39]. SGA was defined as a birth weight under the 10th
centile.
MAP was calculated by adding 1/3 of the pulse pressure (difference
between diastolic and systolic blood pressure) to the diastolic pressure:
MAP = 1/3 (SBP-DBP) + DBP.
2.3. Sample analysis
Sample analysis for the Pittsburgh group was performed at R&D
Systems, Minneapolis, MN, USA. The Dutch group was analyzed at the
Laboratory for Prenatal Screening, National Institute for Public Health
and the Environment, The Netherlands. In both groups samples were
analyzed blinded for outcome in duplicate using the Human relaxin-2
Quantikine enzyme-linked immuno-sorbent assay (ELISA), according to
the manufacturer’s instructions (DRL200, R&D Systems, Abingdon,
United Kingdom). All measurements were above the detection limit of
the ELISA kit (assay range 7.81–500 pg/mL). The ELISA kit has an intra-
and inter-assay coefficient of variance of 3.2% and 7.3% respectively.
Values with an intra-assay coefficient of variance above 15% were ex-
cluded from analysis (Pittsburgh group n = 0; Dutch group n = 2).
2.4. Statistical analysis
Study population characteristics were expressed as numbers and
percentages for categorical variables and median and interquartile
ranges (IQR) for continuous variables (as data were not normally dis-
tributed), and were compared between preeclampsia cases and controls
using Fisher’s Exact and Mann-Whitney U tests, respectively. Bonferroni
corrections for multiple testing were applied when both EO-PE and LO-
PE were compared to controls. Relaxin concentrations were also ex-
pressed as median and IQR. Based on the centiles of the relaxin con-
centrations in the control population, two cut-off points were de-
termined at the 25th (p25) and the 10th (p10) centile, respectively.
Subsequently, to study the association between relaxin concentrations
and preeclampsia, unadjusted and adjusted odds ratios (OR) were
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calculated using multivariate logistic regression analysis. In the Dutch
group, the LO-PE group was selected to have a SGA infant in half of the
cases. Again, multivariate logistic regression analysis was used to study
associations between relaxin and preeclampsia among these subgroups.
Based on the predefined cut-off point of relaxin < p10, detection
rates (sensitivity) were calculated for relaxin as a single biomarker, as
well as in combination with maternal characteristics (prior risk based
on: age, BMI, nulliparity) and MAP.
Statistical analyses were performed using SPSS (release 20.0;
Chicago, IL, USA) and SAS software package (release 9.2; SAS Institute,
Cary, NC, USA).
3. Results
Demographic and clinical characteristics of the study populations
are presented in Table 1. Data from a total of 25 control pregnant and
33 LO-PE women were analyzed in the Pittsburgh group. The control
group consisted of 16 (64%) Caucasian and 9 (36%) African-American;
the LO-PE group 23 (70%) Caucasian and 10 (30%) African-American.
The Dutch group consisted of 469 control pregnant, 57 EO-PE and 95
LO-PE women. Data on ethnicity were not collected in the Dutch group,
but the make-up of the Dutch pregnant population is reported to be
largely Caucasian (84%) [40]. Women who developed preeclampsia
had a significantly higher MAP in both groups. In the Pittsburgh group,
other characteristics did not reach statistical significance. In the Dutch
group there were several statistically significant differences between
the study groups. Preeclamptic women had a higher BMI and were
more often nulliparous. Furthermore, preeclamptic women had more
often a history of hypertensive pregnancy disorders. There was no
significant difference in smoking status between study groups. Pre-
eclamptic women delivered earlier, their infants had a lower birth
weight, and were smaller for gestational age.
3.1. Pilot study in ‘Pittsburgh group’
In the Pittsburgh group relaxin concentrations did not prove to be
significantly different in LO-PE from controls (median with IQR for
controls 802 [571–966] pg/mL and LO-PE 783 [452–1081] pg/mL;
p = 0.561). Moreover, relaxin concentrations showed no correlation
with gestational age in the control group (Fig. 1). However,
Table 1
Study population characteristics in unaffected and preeclampsia pregnancies of the Pittsburgh and Dutch group. Values are presented as median (IQR) or number
(%).
Characteristics Pittsburgh group Dutch group
Controls LO-PE Controls EO-PE LO-PE$
n = 25 n = 33 n = 469 n = 57 n = 95
Pregnancy characteristics:
Maternal age (y) 25.5 (20–32) 23.2 (20–31) 33 (30–35) 33 (30–36) 32 (30–36)
Maternal BMI at sampling (kg/m2) 23.1 (21.3–26.1) 26.5 (22.6–31.0) 22.8 (20.9–24.9) 24.7 (21.9–28.9)* 23.6 (21.2–26.3)*
Nulliparity 20 (80.0%) 25 (75.8%) 217 (46.3%) 46 (80.7%)* 69 (72.6%)*
Gestation at sampling (d) 52 (48–69) 61 (49–71) 88 (85–91) 85 (77–89)* 85 (81–89)*
First trimester systolic blood pressure (mmHg) 120 (112–125) 148 (143–156)* 110 (100–120) 120 (110–130)* 118 (110–122)*
First trimester diastolic blood pressure (mmHg) 71 (68–76) 90 (83–94)* 65 (60–70) 70 (70–80)* 70 (66–78)*
First trimester MAP (mmHg) 80 (77.0–86.3) 87 (82.7–90.3)* 80 (73.3–86.7) 88.2 (83.3–96.7)* 86.7 (81.8–91.7)*
Smoking 7 (28%) 12 (36.4%) 19 (4.1%) 4 (7.0%) 6 (6.3%)
Birth characteristics:
Gestation at delivery (d) 272 (267–277) 272 (260–279) 283 (277–288) 222 (213–230)* 265 (256–275)*
Sex, n female (%) 8 (32%) 15 (45%) 238 (50.7%) 29 (50.9%) 44 (46.3%)
Birthweight (gr) 3164 (2979–3413) 2948 (2638–3590) 3560 (3250–3820) 1300 (1040–1610)* 2650 (2155–3065)*
Birthweight centile 55.5 (25.2–76.5) 36.8 (19.0–68.2) 57.9 (33.7–79.1) 26.4 (11.9–52.8)* 13.8 (4.1–45.6)*
Birthweight < p3 (%) 0 (0%) 0 (0%) 9 (1.9%) 3 (5.3%) 20 (21.1%)*
Birthweight < p10 (%) 1 (4.0%) 3 (9.1%) 44 (9.4%) 12 (21.1%)* 47 (49.5%)*
Fisher’s exact tests and Mann-Whitney U tests, both with post hoc Bonferroni correction were used for statistical analysis. BMI: Body Mass Index; MAP: Mean Arterial
Pressure; CS: Caesarean Section; < p3: below 3rd percentile; < p10: below 10th percentile; EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia. *
p < 0.05. $ The LO-PE group was selected to have a small for gestational age (SGA) infant in half of the cases.
Fig. 1. Distribution of relaxin concentrations in unaffected (green dots) and LO-PE pregnancies (blue triangles) in the Pittsburgh group. (A) Presented as a function of
gestational age. (B) Summary plot per outcome group, indicated are median concentrations with interquartile range. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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significantly more women in the LO-PE group had a relaxin con-
centration below the 10th centile (p10; < 495.4 pg/mL) of control
pregnancies, OR 4.19 (1.03–17.0) (Table 2). When the OR was adjusted
for gestational age at sampling, BMI and smoking it increased to 5.29
(1.10–25.5). A cut-off value at the p25 of the control group
(< 570.8 pg/mL) showed a similar trend, but did not reach statistical
significance (OR unadjusted 1.81 and adjusted 2.12, respectively).
3.2. Validation in ‘Dutch group’
The same analysis strategy was applied for the independent data of
the Dutch group. Relaxin concentrations were not different between
EO-PE, LO-PE and controls (median with IQR for controls 1663
[1342–2061] pg/mL, EO-PE 1739 [1398–2230] pg/mL and LO-PE 1604
[1198–2198] pg/mL; p = 0.543 for EO-PE and p = 0.456 for LO-PE).
Again there was no change in relaxin concentration with gestational
age (Fig. 2). Relaxin concentrations were higher in the Dutch group
compared to the Pittsburgh group; the latter was sampled on average
4–5 weeks earlier in pregnancy. As in the Pittsburgh group, a relaxin
concentration below p10 (< 1054.4 pg/mL) was associated with LO-
PE: OR 2.1 (p = 0.015) and adjusted OR 2.03 (p = 0.032) (Table 2). A
cut-off value at p25 (< 1342 pg/mL) resulted in an OR of 1.60
(p = 0.05), which was not significant after adjustment (OR 1.50;
p = 0.124). There was no significant association with EO-PE.
In the LO-PE group we performed a sub-analysis to assess the in-
fluence of an SGA infant (Table 3). In LO-PE women who delivered an
SGA infant (LO-PE with SGA), the correlation with a relaxin con-
centration below p25 and p10 was stronger, with adjusted ORs of 2.17
(p = 0.034) and 3.18 (p = 0.005) respectively. In LO-PE women
without a SGA infant (LO-PE without SGA), the correlations with a
relaxin concentration below p25 and p10 were lost (adjusted OR’s of
1.06, p = 0.871; and 1.30, p = 0.582 respectively). We did not include
Table 2
Association of relaxin concentration with EO-PE and LO-PE at different cut-off values (p25, p10 of the control population) in the Pittsburgh and Dutch group.
Pittsburgh group - LO-PE Unadjusted Adjusted
controls (n = 25) cases (n = 33) OR 95% CI p-value OR 95% CI p-value
n < p25 (< 570.8 pg/mL) 6 14 1.81 0.57–5.77 0.316 2.12 0.58–7.77 0.157
n < p10 (< 495.4 pg/mL) 3 13 4.19 1.03–17.0 0.045 5.29 1.10–25.5 0.038
Dutch group - EO-PE Unadjusted Adjusted
controls (n = 469) cases (n = 57) OR 95% CI p-value OR 95% CI p-value
n < p25 (< 1342 pg/mL) 117 14 0.98 0.52–1.89 0.949 0.79 0.36–1.76 0.567
n < p10 (< 1054 pg/mL) 47 8 1.47 0.66–3.28 0.352 1.45 0.54–3.90 0.465
Dutch group - LO-PE Unadjusted Adjusted
controls (n = 469) cases (n = 95) OR 95% CI p-value OR 95% CI p-value
n < p25 (< 1342 pg/mL) 117 33 1.60 1.00–2.57 0.05 1.50 0.90–2.52 0.124
n < p10 (< 1054 pg/mL) 47 18 2.10 1.16–3.81 0.015 2.03 1.06–3.88 0.032
Odds ratios were adjusted for gestational age at sample collection, Body Mass Index (BMI) and smoking. < p25: below 25th percentile; < p10: below 10th
percentile; OR: Odds ratio; CI: confidence interval; EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia.
Fig. 2. Distribution of relaxin concentrations in unaffected (green dots), EO-PE (red squares) and LO-PE pregnancies (blue triangles) in the Dutch group. (A)
Presented as a function of gestational age. (B) Summary plot per outcome group, (+) with SGA infant (−) without SGA infant. Indicated are median concentrations
with interquartile range. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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a SGA sub-analysis for EO-PE because of low case numbers (12 out of 57
EO-PE cases delivered a SGA infant), and lack of correlation between
low relaxin concentrations (< p10) with EO-PE in the initial analysis.
3.3. Screening performance in ‘Dutch group’
In the Dutch group, prediction models for the complete LO-PE group
(n = 95) and for the subgroup of LO-PE with SGA (n = 47) were fitted
based on maternal characteristics (prior risk), MAP and relaxin < p10
(Table 4). Comparison of the performance of these models showed that
the highest detection rate (DR) for the complete LO-PE group was ob-
tained for the model combining maternal characteristics, MAP and re-
laxin < p10, with a DR of 45.1% at a false positive rate (FPR) of 10%
(16.6% gain in DR compared to the model using prior risk only; 2.6%
gain in DR compared to the model using prior risk + MAP). For the
prediction of LO-PE with SGA the best performing model combined
maternal characteristics with relaxin < p10 only, with a DR of 37.1%
at a FPR of 10% (2.7% gain in DR compared to the model using prior
risk only).
3.4. Correlation of relaxin with other circulating biomarkers
We previously reported pregnancy-associated plasma protein A
(PAPP-A), free beta human chorionic gonadotrophin (fβ-hCG), A
Disintegrin And Metalloprotease 12 (ADAM-12) and placental growth
factor (PlGF) concentrations for the study subjects of the Dutch group
[18], enabling us to correlate relaxin concentrations with these other
circulating biomarkers. There was a statistically significant positive, but
low correlation of relaxin with PAPP-A (Spearman’s rho 0.098;
p = 0.014) and fβ-hCG (Spearman’s rho 0.137; p = 0.001). There was
no correlation between relaxin and ADAM-12 (Spearman’s rho 0.072;
p = 0.074) and between relaxin and PlGF (Spearman’s rho 0.065;
p = 0.111).
4. Discussion
To the best of our knowledge, this two-stage study, in which pa-
tients were well-characterized, is the first to investigate relaxin as a
predictor for women destined to develop preeclampsia. We observed a
clear association of low (lowest centile: < p10) first trimester relaxin
concentrations with LO-PE (adjusted OR 2.0–5.3) but not with EO-PE.
However, in a multivariate model, a relaxin concentration below the
10th centile only showed a ~2.5% gain in detection rate of prediction
models for LO-PE, which combined maternal characteristics (prior risk
based on: age, BMI, nulliparity) with or without MAP.
Preeclampsia in combination with a SGA infant is suggestive of a
distinct and more severe (placental) pathophysiology [41,42], which
generally results in different performance of biomarkers for this sub-
group [35,43]. A low relaxin concentration (< p10) indeed showed a
stronger association with LO-PE in combination with SGA, compared to
LO-PE without SGA. This, as well as the association between low relaxin
concentration with LO-PE but not with EO-PE, underscores the het-
erogenic nature of the preeclampsia syndrome and is in line with ac-
cumulating evidence for differences in the underlying etiology. EO-PE is
thought to result from poor placental development (placental pre-
eclampsia) [10], whereas LO-PE is more likely to result from poor
maternal systemic cardiovascular adaptations to pregnancy (maternal
preeclampsia) [44,45]. However, logic dictates that this pathophysio-
logic division is likely to be graded and not absolute, with no definite
gestational age break point. Nevertheless, the association of low relaxin
with LO-PE but not EO-PE may indicate that adequate circulating re-
laxin levels are more important for the maternal systemic vascular
adaptations to pregnancy, but less so for processes at the maternal-fetal
interface that guarantee the establishment of a functional placenta.
The finding of a stronger association between low circulating re-
laxin and LO-PE in combination with SGA may at first glance seem
paradoxical. However, given the higher occurrence of LO-PE compared
to EO-PE [8], SGA is more commonly associated with LO-PE. On a
Table 3
Association of relaxin concentration with LO-PE pregnancies with and without a small for gestational age (SGA) infant at different cut-off values (p25, p10 of the
control population) in the Dutch group.
Dutch group - LO-PE - SGA+ Unadjusted Adjusted
controls (n = 469) cases (n = 47) OR 95% CI p-value OR 95% CI p-value
n < p25 (< 1342 pg/mL) 117 20 2.23 1.21–4.12 0.011 2.17 1.06–4.45 0.034
n < p10 (< 1054 pg/mL) 47 12 3.08 1.50–6.34 0.002 3.18 1.41–7.20 0.005
Dutch group - LO-PE - SGA- Unadjusted Adjusted
controls (n = 469) cases (n = 48) OR 95% CI p-value OR 95% CI p-value
n < p25 (< 1342 pg/mL) 117 13 1.12 0.57–2.18 0.745 1.06 0.53–2.13 0.871
n < p10 (< 1054 pg/mL) 47 6 1.28 0.52–3.18 0.591 1.30 0.51–3.31 0.582
Odds ratios were adjusted for gestational age at sample collection, Body Mass Index (BMI) and smoking. < p25: below 25th percentile; < p10: below 10th
percentile; OR: Odds ratio; CI: confidence interval; LO-PE: late-onset preeclampsia; SGA+: with small for gestational age infant; SGA-: without small for gestational
age infant.
Table 4
Screening performance of relaxin for LO-PE. Model predicted LO-PE detection rate for a false positive rate of 10% with prior risk, MAP and relaxin < p10 in the
complete LO-PE group and in the LO-PE group with a SGA infant.
Dutch group LO-PE - all (n = 95) LO-PE - SGA+ (n = 47)
DR (%) AUC 95% CI DR (%) AUC 95% CI
Prior risk 28.5 0.722 0.661–0.783 34.4 0.765 0.683–0.847
Prior risk + MAP 42.5 0.798 0.742–0.854 31.0 0.751 0.668–0.834
Prior risk + Relaxin < p10 30.9 0.729 0.668–0.790 37.1 0.791 0.712–0.870
Prior risk + MAP + Relaxin < p10 45.1 0.801 0.745–0.857 31.0 0.760 0.678–0.842
Prior risk of preeclampsia was based on: maternal age, BMI and nulliparity. MAP: mean arterial pressure; < p10: below 10th percentile; DR: detection rate; AUC: area
under the curve; CI: confidence interval; LO-PE: late-onset preeclampsia; SGA+: with small for gestational age infant.
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pathophysiological basis, low circulating relaxin in early human preg-
nancy may impair maternal vascular adaptation, thereby compromising
uterine perfusion and fetal growth [46]. In support of this hypothesis,
relaxin was shown to increase uterine blood flow velocity and to in-
crease uterine arterial compliance in conscious rats [47].
There was a low but significant correlation between relaxin and
placenta-derived biomarkers measured in the 469 control samples of
the Dutch cohort: Pregnancy-associated plasma protein A (PAPP-A) and
free beta human chorionic gonadotrophin (fb-hCG). Adding relaxin to a
prediction model of PAPP-A and/or fb-hCG (including MAP and prior
risk) did not significantly improve the performance of these prediction
models to predict EO-PE or LO-PE (data not shown). No correlation was
found between concentrations of relaxin with A Disintegrin And
Metalloprotease 12 (ADAM-12) and placental growth factor (PlGF)
[35]. Relaxin concentrations showed a slight inverse correlation with
BMI and MAP (data not shown).
Overall strengths of the present study are the two well-characterized
study populations with similar assays run in blinded fashion, and the
consistency in resulting findings of both groups adding to the general-
izability. The strengths of the Pittsburgh group are the very well
characterized population with a jury of investigators reviewing and
confirming the diagnosis of preeclampsia. Limitations of the Pittsburgh
group include the relatively small sample size, the selection of parti-
cipants in a tertiary clinical setting and the lack of EO-PE cases.
Furthermore, preeclampsia cases in this group had a relatively high BMI
adding to the stronger association with low relaxin concentrations than
found in the Dutch group. The Dutch group was much larger, includes
both EO-PE and LO-PE cases, and comprises an unselected general
population, as samples derived from surplus material of the national
Dutch first trimester down syndrome screening program. Consequently
this population has a relatively high maternal age (~33 years) com-
pared to the Pittsburgh group which may affect study comparison, al-
though both studies were internally controlled. Moreover, the gesta-
tional age at sampling was on average 4–5 weeks later in pregnancy in
the Dutch group than the Pittsburgh group. This may partly explain
differences in absolute relaxin concentrations between these studies, as
circulating relaxin concentrations are known to rise after ovulation
until the end of the first trimester [18,19]. Furthermore, other differ-
ences in study population characteristics of the Pittsburgh compared to
the Dutch group (predominately Caucasian) may also have contributed.
In conclusion, relaxin only provides little improvement in perfor-
mance of prediction models for LO-PE and no improvement for EO-PE,
which does not support clinical implementation. The association be-
tween low relaxin concentrations (< p10) with LO-PE, particularly
when complicated by a SGA infant may indicate a potential patho-
physiologic role for deficient circulating relaxin in one subtype of
preeclampsia.
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